Recombinant human thrombopoietin (rh-TPO) for the prevention of severe thrombocytopenia induced by high-dose cytarabine: a prospective, randomized, self-controlled study. [electronic resource]
Producer: 20190624Description: 2821-2828 p. digitalISSN:- 1029-2403
- Adult
- Aged
- Antimetabolites, Antineoplastic -- administration & dosage
- Cytarabine -- administration & dosage
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Female
- Humans
- Lymphoma, Non-Hodgkin -- blood
- Male
- Middle Aged
- Platelet Count
- Platelet Transfusion -- statistics & numerical data
- Prospective Studies
- Recombinant Proteins -- administration & dosage
- Thrombocytopenia -- blood
- Thrombopoietin -- administration & dosage
- Treatment Outcome
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.